coramitug

Coramitug (formerly PRX004 or NNC6019-0001) is a humanized monoclonal antibody designed to treat transthyretin amyloidosis (ATTR), specifically transthyretin amyloid cardiomyopathy (ATTR-CM). Developed by Novo Nordisk following its acquisition from Prothena, the antibody specifically targets and binds to misfolded, pathogenic forms of the transthyretin (TTR) protein. By binding to these misfolded proteins and amyloid deposits, coramitug promotes their clearance through antibody-mediated phagocytosis. Importantly, it is engineered to avoid binding to the native, functional tetrameric form of TTR, thereby preserving its normal physiological function. It is currently being evaluated in the Phase 3 CLEOPATTRA trial for its impact on cardiovascular outcomes in patients with ATTR-CM.

Brand names

Coramitug

Other names

coramitug